Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Lymphoma, Mantle-Cell × Lenalidomide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 6 Lymphoma, Non-Hodgkin 3 Lymphoma, Follicular 3 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, B-Cell, Marginal Zone 2 Lymphoma 2 Neoplasms 1 Lymphoma, Mantle-Cell 1

Interventions

Rituximab 3 acalabrutinib 2 Bendamustine Hydrochloride 2 zanubrutinib 1 venetoclax 1 umbralisib 1 ublituximab 1 pirtobrutinib 1 fludarabine 1 brexucabtagene autoleucel 1 axicabtagene ciloleucel 1 Lenalidomide 1 Cyclophosphamide 1 Appointments and Schedules 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01996865 2025-07-10

MAGNIFY

Celgene

Phase 3 Completed

503 enrolled 18 charts 1 FDA

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡